Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results

Heczey, A; Xu, X; Courtney, AN; Tian, GW; Barragan, GA; Guo, LJ; Amador, CM; Ghatwai, N; Rathi, P; Wood, MS; Li, YC; Zhang, CC; Demberg, T; Di Pierro, EJ; Sher, AC; Zhang, HM; Mehta, B; Thakkar, SG; Grilley, B; Wang, T; Weiss, BD; Montalbano, A; Subramaniam, M; Xu, CL; Sachar, C; Wells, DK; Dotti, G; Metelitsa, LS

Heczey, A; Metelitsa, LS (通讯作者)，Baylor Coll Med, Ctr Adv Innate Cell Therapy, Dept Pediat, Houston, TX 77030 USA.;Heczey, A; Metelitsa, LS (通讯作者)，Baylor Coll Med, Ctr Cell & Gene Therapy, Dept Med, Houston, TX 77030 USA.

NATURE MEDICINE, 2023; 29 (6): 1379

Abstract

V alpha 24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced by chimeric antigen receptors (CARs). Here we repor......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索